Real-World Outcomes of First-Line Pembrolizumab Monotherapy in Metastatic NSCLC with High PD-L1 Expression (TPS ≥ 50%): A Multicenter Study from Serbia

<b>Background:</b> Pembrolizumab monotherapy is the standard first-line treatment for metastatic non-small cell lung cancer (NSCLC) patients whose tumors express a PD-L1 tumor proportion score (TPS) of ≥50%. However, real-world data regarding its effectiveness outside of clinical trials, particularl...

Повний опис

Бібліографічні деталі

Автори:	Filip Marković, Mihailo Stjepanović, Milan Rančić, Marina Cekić, Milica Kontić
Формат:	Artigo
Мова:	Inglês
Опубліковано:	MDPI AG 2025-05-01
Серія:	Biomedicines
Предмети:	first-line high PD-L1 expression immune check-point inhibitors non-small cell lung cancer pembrolizumab predictive factors
Онлайн доступ:	https://www.mdpi.com/2227-9059/13/5/1175
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!